Loading stock data…
Aethlon Medical (AEMD)
$0.86-0.01 (-1.41%)
Market OpenUpdated 2:08 PM EDT
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aethlon Medical, Inc. in the Healthcare sector is trading at $0.86 with a market capitalization of $5M. Wall Street consensus targets $3.25 (2 analysts), implying a +277.5% move over the next 12 months. The stock is currently near its 52-week low of $0.80, remaining 74.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 13 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +277.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 13) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.06M↓ | -$1.51M↑ | -$1.79M↑ | -$2.00M↓ | -$1.81M |
| Net Income | -$2.02M↓ | -$1.49M↑ | -$1.76M↑ | -$6.25M↓ | -$1.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for ap...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-171.64%
Volume
Today's trading volume
164,595
Recent News
Aethlon Medical advances Hemopurifier study as final trial cohort nears completion
Aethlon Medical CEO James Frakes joined Steve Darling from Proactive to discuss the company’s Hemopurifier® technology and the progress of its ongoing clinical program evaluating the device’s potential role in cancer treatment. The Hemopurifier is an investigational medical device designed to remove harmful particles from the bloodstream. Frakes explained that the technology works alongside existing dialysis and blood-pumping systems, using a plant lectin-based mechanism to bind and remove viruses as well as cancer-associated extracellular vesicles (EVs), which are believed to play a role in tumor growth, immune suppression, and the spread of cancer. Aethlon has received two FDA Breakthrough Device Designations, one targeting life-threatening viral infections with no approved treatments and another focused on oncology applications. While the company initially concentrated on infectious diseases such as Ebola, Frakes said its primary development focus has now shifted toward cancer treatment. A key area of interest is the company’s ongoing safety study in Australia, which is now more than two-thirds complete. The trial is investigating whether removing cancer-associated EVs from the bloodstream can help restore immune system function and potentially reduce metastatic disease progression. “The concept is removing these EVs helps the body fight against metastasis, the spread of cancer,” Frakes said. The study consists of three cohorts evaluating increasing treatment frequency. The first two cohorts have been completed, while enrollment and treatment in the third cohort are currently underway. Researchers are also analyzing changes in EV levels and immune system biomarkers with laboratory support from the University of Sydney. Frakes said Aethlon expects to complete the final cohort during the summer, followed by data analysis and regulatory submissions in Australia and the United States later in 2026. Management believes the results could provide important insights into the potential of Hemopurifier as a novel adjunct therapy in oncology. #proactiveinvestors #aethlonmedical #nasdaq #aemd #medicaltherapeutics #Hemopurifier #CancerResearch #Oncology #Biotech #MedicalDevices #ClinicalTrials #HealthcareInnovation #Immunotherapy #CancerTreatment
Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...
Aethlon Medical Inc (AEMD) reports significant progress in clinical trials and cost management, despite ongoing financial hurdles.
Aethlon (AEMD) Q4 2026 Earnings Transcript
James Frakes: Thank you, operator, and good afternoon, everyone. My name is Jim Frakes, and I'm the Chief Executive Officer and Chief Financial Officer of Aethlon Medical. At 4:15 p.m. Eastern Time today, Aethlon Medical released financial results for its fiscal year ended March 31, 2026.
Aethlon Medical Inc (AEMD) Q3 2026 Earnings Call Highlights: Progress in Oncology Trials and ...
Aethlon Medical Inc (AEMD) reports significant strides in oncology trials and research platform expansion, despite facing increased operating expenses.
Aethlon Medical, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aethlon Medical, Inc.'s Q3 2026 earnings call